
-
Taysha Gene Therapies NASDAQ:TSHA Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, Taysha Gene Therapies leverages its fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives.
Location: | Website: tayshagtx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
235.3M
Cash
157.7M
Avg Qtr Burn
-19.76M
Short % of Float
18.74%
Insider Ownership
18.34%
Institutional Own.
83.22%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TSHA-102 Details Rett syndrome | Phase 1/2 Data readout | |
TSHA-102 Details Rett syndrome | Phase 1/2 Data readout | |
TSHA-120 Details Giant Axonal Neuropathy | Failed Discontinued | |
TSHA-118 Details Batten Disease | Failed Discontinued | |
TSHA-101 Details GM2 gangliosidosis | Failed Discontinued |